Mesenchymal Stem Cells Market Size & Share, by Type (Human MSCs, Mouse MSCs, Rat MSCs); Source (Bone Marrow, Umbilical Cord, Adipose Tissue, Molar Cells); Application (Drug Discovery, Injuries, Cardiovascular Myocardial Infarction) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3933
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Companies Dominating the Mesenchymal Stem Cells Landscape

    • Bio-Techne Corporation
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck KGaA
    • Genlantis, Inc.
    • Celprogen Corporation
    • PromoCell GmbH
    • Cyagen US Inc.
    • Plus Therapeutics, Inc.
    • Human Longevity, Inc.
    • Thermo Fisher Scientific Inc.
    • Pluristem Therapeutics Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • Pluristem Therapeutics Inc. the leading biotechnology company in regenerative medicine, announced the commencement of its multinational Phase III multicenter research on muscle regeneration. The study has been conducted to support muscle regeneration associated with notable trauma such as hip fractures. The company is further noticed to develop placenta-based cell therapy products.

  • PromoCell GmbH to lead research on immunotherapies through all human primary cells and blood & stem cells, including MHC class I genes HLA-A, -B, and -C.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3933
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising demand for stem cell treatment in type 1 diabetes and the growing prevalence of genetic diseases and disorders are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2023-2035.

The very high cost of stem cell treatment and the possibility of administration site reaction and tumor growth is estimated to be the growth-hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Merck KGaA, Genlantis, Inc., Celprogen Corporation, PromoCell GmbH, Cyagen US Inc., Plus Therapeutics, Inc., Human Longevity, Inc., Thermo Fisher Scientific Inc., Pluristem Therapeutics Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, source, application, and by region.

The umbilical cord segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying